Regulating return

One of the fun and often instructive aspects of BioCentury's job involves finding connections between events. So it wasn't entirely surprising to uncover a link between this week's biotech meeting at the White House and last week's blockbuster deal between Protein Design Labs and Corange Ltd.

Earlier last month, Corange announced that it would relocate the management of Boehringer Mannheim Therapeutics to the U.S., in part to improve its position in the U.S. market and to gain access to technology like that obtained through its deal with PDLI.